Stepronin

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

353 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Stepronin.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Stepronin.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Stepronin.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Stepronin.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Stepronin.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Stepronin.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Stepronin.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Stepronin.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Stepronin.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Stepronin.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Stepronin.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Stepronin.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Stepronin.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Stepronin.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Stepronin.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Stepronin.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Stepronin.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Stepronin.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Stepronin.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Stepronin.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Stepronin.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Stepronin.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Stepronin.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Stepronin.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Stepronin.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Stepronin.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Stepronin.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Stepronin.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Stepronin.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Stepronin.
Cladribine	Stepronin may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Stepronin.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Stepronin.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Stepronin.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Stepronin.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Stepronin.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Stepronin.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Stepronin.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Stepronin.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Stepronin.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Stepronin.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Stepronin.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Stepronin.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Stepronin.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Stepronin.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Stepronin.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Stepronin.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Stepronin.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Stepronin.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Stepronin.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Stepronin.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Stepronin.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Stepronin.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Stepronin.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Stepronin.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Stepronin.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Stepronin.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Stepronin.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Stepronin.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Stepronin.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Stepronin.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Stepronin.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Stepronin.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Stepronin.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Stepronin.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Stepronin.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Stepronin.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Stepronin.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Stepronin.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Stepronin.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Stepronin.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Stepronin.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Stepronin.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Stepronin.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Stepronin.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Stepronin.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Stepronin.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Stepronin.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Stepronin.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Stepronin.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Stepronin.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Stepronin.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Stepronin.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Stepronin.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Stepronin.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Stepronin.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Stepronin.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Stepronin.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Stepronin.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Stepronin.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Stepronin.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Stepronin.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Stepronin.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Stepronin.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Stepronin.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Stepronin.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Stepronin.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Stepronin.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Stepronin.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Stepronin.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual